Strategia Therapeutics Inc

Obsidian Therapeutics Inc, based in Cambridge, MA, is at the forefront of precision cell and gene therapy, utilizing its proprietary cytoDRIVE platform to engineer regulated therapeutic proteins. The company is dedicated to pioneering the next generation of engineered therapeutics to address critical patient needs. With a focus on innovative solutions, Obsidian is advancing its lead clinical program, OBX115, an engineered TIL cell therapy targeting advanced melanoma. The company’s commitment to collaboration and urgency drives its mission to improve patient outcomes through cutting-edge science and technology. Generated from the website

C4 Therapeutics, Inc. is a biotechnology company based in Watertown, MA, specializing in targeted protein degradation. Their innovative approach, known as Targeted Protein Degradation (TPD), aims to develop a new generation of medicines for treating various diseases. Through their TORPEDO platform and focus on target selection, C4 Therapeutics is dedicated to transforming lives by degrading disease-causing proteins. With a strong leadership team, board of directors, and scientific advisory board, C4 Therapeutics is committed to advancing their pipeline of therapies, including CFT7455, CFT1946, and CFT8919. They also collaborate with industry partners such as Roche, Biogen, Betta Merck, and others to further their research and development efforts. At C4 Therapeutics, their values, people, and dedication to scientific progress drive their mission to revolutionize the treatment of diseases through targeted protein degradation.Generated from the website

Remix Therapeutics is a clinical-stage biotechnology company based in Watertown, MA, focused on developing small molecule therapies that modulate RNA processing to address the underlying drivers of diseases, particularly in the oncology space. Founded in 2020, the company aims to transform patients' lives by creating new therapeutic options for conditions with high unmet medical needs. With a proprietary drug discovery platform, Remix Therapeutics harnesses cellular machinery to control RNA processing and identify druggable targets. The company's commitment to scientific integrity and urgency is driven by the belief that patients are counting on innovative solutions to improve their outcomes. Generated from the website